Provectus Biopharma and Antibiotic Resistance

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee Health Science Center to Investigate Small Molecule Rose Bengal Disodium for Antibiotic Resistance

KNOXVILLE, TN, Sept. 09, 2020 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Michio Kurosu, PhD, Professor, Department of Pharmaceutical Sciences at the College of Pharmacy of the University of Tennessee Health Science Center (UTHSC) in Memphis, Tennessee to investigate rose bengal disodium (RBD) targeting of multi-drug resistant (MDR) bacteria. RBD is Provectus’ proprietary lead molecule, and a member of a class of small molecules called halogenated xanthenes that is entirely and wholly owned by the Company.

Dr. Kurosu’s team will undertake in vitro studies on:

The spectrum of RBD activity against drug-susceptible and drug-resistant bacterial strains,
Synergistic activity of combinations of RBD and US Food and Drug Administration-approved antibiotics for Gram-negative bacteria,
The mutation frequency of RBD against bacterial strains, measuring spontaneous bacterial mutations for RBD and these combinations, and
Gene analyses of mutant bacterial strains to understand resistance mechanisms.

Click Link for Story: Provectus and AMR

Leave a Reply

Your email address will not be published. Required fields are marked *